On July 2, Hengrui Pharma rose 3.72% in regular trading, trading at HK$61.5/share, with turnover of HK$49.77 million. The stock gained alongside a broad pharmaceutical sector rally, with CSPC Pharma up over 10%, China Grand Pharma up over 6%, and Hansoh Pharma up nearly 5%.

The movement was driven by a cluster of recent regulatory catalysts. Hengrui's subsidiary received NMPA approval to expand the indication of adebrelimab injection to include perioperative treatment of non-small cell lung cancer (NSCLC), making it the first domestically developed PD-L1 inhibitor approved for this indication in China. Additionally, the company's subsidiary won marketing approval for Cyclosporine Ophthalmic Solution (CyclASol) for dry eye disease, and HRS-4508 tablets — a novel selective tyrosine kinase inhibitor targeting breast and lung cancers — received clinical trial approval for advanced solid tumors, with RMB 81.8 million invested in its development.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)